ArticleAmerican journal of translational research2025
Correlation of serum KLK1 and SOX6 levels with major adverse cardiovascular events in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the relationship between serum kallikrein 1 (KLK1) and SRY-box transcription factor 6 (SOX6) levels and major adverse cardiovascular events (MACE) in patients with ST-segment elevation myocardial infarction (STEMI) following percutaneous coronary intervention (PCI).
methodsA total of 150 STEMI patients who underwent PCI from October 2021 to October 2022 were included in this study. Patients were divided into MACE and Non-MACE groups based on the occurrence of postoperative adverse cardiovascular events. General data, laboratory findings, and imaging results were compared between the two groups. Logistic regression analysis was used to identify factors influencing MACE, which were further used to develop a joint prediction model. ROC curves were plotted to assess the predictive values of the model.
resultsMACE occurred in 20 patients (13.33%). The MACE group had significantly higher Killip grade (P = 0.020), elevated serum levels of cardiac troponin I (cTnI) (P = 0.040), creatine kinase (CK) (P = 0.044), KLK1 (P < 0.001), creatine kinase isoenzyme (CK-MB) (P = 0.043), and SOX6 (P < 0.001), as well as higher Gensini score (P = 0.040) and Grace score (P = 0.045). Logistic regression analysis identified KLK1 (OR = 1.015, P = 0.016) and SOX6 (OR = 1.823, P < 0.001) as independent risk factors for MACE. The combination of KLK1 and SOX6 showed excellent predictive value for MACE, with an AUC of 0.889.
conclusionsElevated levels of KLK1 and SOX6 are associated with an increased risk of MACE. The combined detection of these biomarkers can effectively predict MACE, aiding in early identification and timely intervention for high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.